Revolutionizing Trauma Care with Myriad™
Aroa Biosurgery Limited has made significant strides in the world of trauma and acute care surgery with its innovative product, Myriad™. Recent insights from a prospective study indicate the substantial effectiveness and cost benefits associated with the use of Myriad in complex wound management.
Unveiling the Myriad Augmented Soft Tissue Reconstruction Registry
The Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR) is a groundbreaking initiative designed to collect and analyze data regarding the application of bioscaffolds in intricate reconstruction cases. This sizeable, multicenter observational study has enrolled over 450 patients and provides critical insights into the procedural efficacy of Myriad.
The study, presented under the title "Vascularized Tissue Coverage of Trauma and Acute Care Surgery Defects with Ovine Forestomach Matrix: Interim Results of a Prospective Multicenter Study," thoroughly evaluates Myriad Matrix and Morcells for trauma procedures.
Results that Speak Volumes
In examining a cohort of 49 patients with a total of 61 defects, the findings from four leading trauma centers illustrate the product's efficacy. These centers are notable for handling some of the most challenging trauma cases, where wounds can cover extensive areas and are often contaminated.
The results revealed that patients receiving treatment with Myriad achieved complete vascularized tissue coverage within a median time frame of just 22.5 days, often requiring only a single product application. Notably, there were no complications related to the device, emphasizing the safety of Myriad in these high-stakes scenarios.
Cost-Effectiveness Compared to Alternatives
A significant aspect of the study focused on comparing the cost and performance of Myriad with other bioscaffolds used in trauma reconstruction and acute care surgery. According to the published data, Myriad emerges as a more economical option per centimeter, demonstrating outcomes that are at least on par with, if not superior to, other available products.
Expert Opinions on Myriad's Value
Dr. Michael Cormican, a participating study author and trauma surgeon, highlighted the validation provided by the prospective data regarding Myriad's impact on patient care. He notes, 'This prospective data provides validation to what we were already seeing in surgical practice, that Myriad offers a cost-effective solution to improve coverage and healing of complex trauma defects without adding risk to the patient.'
Brian Ward, CEO of Aroa, expressed excitement over the publication, stating, 'We're very pleased to see this third study published from our ongoing MASTRR study. The evidence underscores both the effectiveness of Myriad in complex trauma procedures and its potential to lower the total cost of care for hospitals. With over 140,000 trauma procedures performed annually in the US, and a total addressable market of approximately US$450 million, this represents a sizable growth opportunity and is a strategic focus area for AROA.'
Strengthening Evidence for AROA ECM™
This recent publication fortifies the existing knowledge surrounding the effectiveness, versatility, and economic viability of AROA ECM™ in treating complex wounds. It adds to a rich body of more than 116 peer-reviewed studies that validate AROA ECM's extensive applicability, including findings related to other surgeries, showcasing significant quality-of-life improvements and cost efficiencies.
About AROA™
Aroa Biosurgery stands at the forefront of soft-tissue regeneration, driven by a mission to enable regenerative healing for all. The company specializes in the development, manufacture, sale, and distribution of medical and surgical solutions tailored to enhance healing in complex wounds and tissues.
Grounded in proprietary AROA ECM™ technology, their bioscaffold, derived from ovine forestomach, has been employed in over 7 million applications globally. Aroa strategically distributes its products in the US market through its dedicated sales team and partnership with TELABio, Inc.
With its inception in 2008, AROA, headquartered in Auckland, New Zealand, is publicly traded on the Australian Securities Exchange under the ticker ASX: ARX.
Frequently Asked Questions
What is the Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR)?
The MASTRR is a multicenter observational study aimed at collecting data on the effectiveness of Myriad® in complex wound surgeries.
How does Myriad™ compare to other bioscaffolds?
Research indicates that Myriad™ tends to be more cost-effective and achieves comparable or superior clinical outcomes compared to alternatives.
What outcomes were achieved by patients using Myriad in the study?
Patients treated with Myriad achieved full vascularized tissue coverage within a median of 22.5 days, often after just one application, with no related complications.
Who can benefit from Myriad™ in trauma care?
Myriad™ can greatly benefit patients with complex trauma cases, especially those suffering from extensive or contaminated wounds.
What is Aroa Biosurgery's mission?
Aroa Biosurgery's mission is to unlock regenerative healing for everyone through the development of advanced medical solutions for soft tissue reconstruction.
